Last reviewed · How we verify
LEAF-4L6715
LEAF-4L6715 is a small molecule that targets the SGLT2 receptor.
LEAF-4L6715 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | LEAF-4L6715 |
|---|---|
| Also known as | Liposomal transcrocetin |
| Sponsor | LEAF4Life, Inc. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, LEAF-4L6715 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly useful in the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital mycotic infections
- Increased risk of urinary tract infections
Key clinical trials
- Efficacy and Safety of LEAF-4L6715 for Acute Respiratory Distress Syndrome (PHASE3)
- A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LEAF-4L6715 CI brief — competitive landscape report
- LEAF-4L6715 updates RSS · CI watch RSS
- LEAF4Life, Inc. portfolio CI